1. Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment
- Author
-
V. Robles, Pilar Nos, Claudia Herrera-de Guise, Alicia Algaba, Yolanda Ber Nieto, Guillermo Bastida, Esteban Sáez-González, Fernando Gomollón, Jose Manuel Soares, Fernando Bermejo, Institut Català de la Salut, [Bastida G] Department of Gastroenterology, CIBEREHD, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain. [Herrera-de Guise C, Robles V] Unitat d'Atenció a la Colitis de Crohn, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Algaba A] Department of Gastroenterology, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Hospital Universitario de Fuenlabrada, 28046 Madrid, Spain. [Ber Nieto Y] Department of Gastroenterology, Hospital Universitario San Jorge, 22004 Huesca, Spain. [Soares JM] Department of Gastroenterology, Hospital Pedro Hispano, 4454-509 Matosinhos, Portugal, Vall d'Hebron Barcelona Hospital Campus, and Servicio de Digestivo. Hospital Universitario de Fuenlabrada
- Subjects
enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo del hierro::anemia ferropénica [ENFERMEDADES] ,Male ,Inorganic Chemicals::Elements::Metals, Heavy::Iron [CHEMICALS AND DRUGS] ,Administration, Oral ,Gastroenterology ,Inflammatory bowel disease ,Ferric Compounds ,Intestins - Inflamació - Tractament ,enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal [ENFERMEDADES] ,Hemoglobins ,Enfermedades Inflamatorias del Intestino ,0302 clinical medicine ,iron deficiency ,Quality of life ,Surveys and Questionnaires ,Compuestos de Hierro ,Anèmia ferropènica - Tractament ,TX341-641 ,Prospective Studies ,Prospective cohort study ,Depression (differential diagnoses) ,Aged, 80 and over ,Nutrition and Dietetics ,Anemia, Iron-Deficiency ,sucrosomial iron ,Iron deficiency ,Middle Aged ,anemia ,humanities ,compuestos inorgánicos::elementos::metales pesados::hierro [COMPUESTOS QUÍMICOS Y DROGAS] ,Anemia Ferropénica ,Treatment Outcome ,Tolerability ,030220 oncology & carcinogenesis ,Other subheadings::Other subheadings::/administration & dosage [Other subheadings] ,030211 gastroenterology & hepatology ,Female ,Adult ,medicine.medical_specialty ,Anemia ,Iron ,Article ,03 medical and health sciences ,Young Adult ,inflammatory bowel disease ,Internal medicine ,medicine ,Humans ,Ferro - Metabolisme - Ús terapèutic ,Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases [DISEASES] ,Aged ,Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores] ,Nutrition. Foods and food supply ,business.industry ,iron supplementation ,Nutritional and Metabolic Diseases::Metabolic Diseases::Iron Metabolism Disorders::Anemia, Iron-Deficiency [DISEASES] ,medicine.disease ,Inflammatory Bowel Diseases ,Trace Elements ,Iron-deficiency anemia ,Dietary Supplements ,Quality of Life ,business ,Iron Compounds ,Food Science - Abstract
Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits (p <, 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients’ QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%), they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients’ QoL. In conclusion, SI should be considered in IDA–IBD patients.
- Published
- 2021
- Full Text
- View/download PDF